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Visceral obesity is a relevant pathological condition closely associated with high risk of atherosclerotic vascular disease including
myocardial infarction and stroke. The increased vascular risk is related also to peculiar dysfunction in the endocrine activity of
adipose tissue responsible of vascular impairment (including endothelial dysfunction), prothrombotic tendency, and low-grade
chronic inﬂammation. In particular, increased synthesis and release of diﬀerent cytokines, including interleukins and tumor
necrosis factor-α (TNF-α), and adipokines—such as leptin—have been reported as associated with future cardiovascular events.
Since vascular cell dysfunction plays a major role in the atherothrombotic complications in central obesity, this paper aims at
focusing, in particular, on the relationship between platelets and vascular smooth muscle cells, and the impaired secretory pattern
of adipose tissue.
1.Introduction
Subjects aﬀected by central obesity (i.e., by intra-abdominal
fat excess) are characterized by insulin resistance, metabolic
disorders, and vascular abnormalities which cooperate to
induce high cardiovascular risk [1–3].
The so-called “metabolic syndrome”, deﬁned on the basis
of a combination of central obesity, glucose intolerance,
atherogenic dyslipidemia, and arterial hypertension [3, 4], is
present in the large majority of these subjects.
In central obesity, abnormalities in the extent and distri-
bution of fat mass are associated with a peculiar dysfunction
of adipose tissue, responsible—together with the insulin
resistance—of alterations of vascular function (including
endothelial dysfunction), pro-thrombotic tendency, low-
grade chronic inﬂammation, and oxidative stress: these
defects, frequently associated as a cluster, represent the main
pathogenetic link between obesity and the increased risk of
athero-thrombotic events [5–7].
Omental adipose tissue, which comprises both
adipocytes and a stromovascular cell fraction, is not an
inert lipid storage site, but a dynamic endocrine organ
able to synthesize and secrete many bioactive peptides—
collectively named “adipocytokines”—deeply involved in
the metabolic, vascular, and immunological homeostasis by
paracrine and endocrine mechanisms [2, 6, 8–10].
Some molecules, directly synthesized by adipocytes and
called “adipokines” (i) control energy balance and appetite,
and inﬂuence insulin sensitivity via endocrine mechanisms,
and (ii) modulate adipocyte size/number and angiogenesis
via paracrine mechanisms, thus exerting a major role in the
regulation of fat mass [10, 11]. Furthermore, they can also
exert a role in the control of blood pressure, lipoprotein
metabolism, coagulation, immunity and inﬂammation [5,
11].
Other peptides belonging to the cytokine group—
produced and released by the stromal vascular com-
ponents of adipose tissue (i.e., lymphocytes, ﬁbroblasts,
macrophages, endothelial cells, and preadipocytes) [8, 9, 12–
14]—aremainlyinvolvedinlocalandsystemicinﬂammation
[8, 13–16]. The increase in abdominal adipose tissue mass
dysregulates both adipokine and adipocytokine secretion
patterns [10, 14].2 Mediators of Inﬂammation
With the exception of the insulin sensitizing pep-
tide adiponectin, adipokine production and secretion are
increased in central obesity [10, 11, 15]: this fact plays
a pivotal role both in the pathogenesis of cardiovascular
damage through adverse eﬀects on hemostatic balance and
vascular function [5, 6, 11], and in the ampliﬁcation of
inﬂammatory processes in vascular and nonvascular tissues
[11, 13, 15].
Also, cytokine release is enhanced: this phenomenon
is attributable to increased prevalence of hypertrophied
adipocytes with altered adipokine synthesis and secretion,
local hypoxia, as well as activation of resident inﬂammatory
cells and macrophages [14, 15].
Inparticular,adiposetissuefromindividualswithcentral
obesity synthesizes and releases increased amount of
(i) proinﬂammatory chemokines and cytokines, such
as Monocyte Chemoattractant Protein-1 (MCP-
1), macrophage migration inhibitory factor (MIF),
tumor necrosis factor-α (TNF-α ), and interleukins,
including interleukin-1β (IL-1β ) and interleukin-6
(IL-6) [15];
(ii) procoagulant and proinﬂammatory mediators such
as tissue factor (TF) and plasminogen activator
inhibitor-1 (PAI-1) [15];
(iii) vasoactive substances such as angiotensinogen and
endothelin-1 (ET-1) [17, 18];
(iv) molecules involved in the pathogenesis of insulin
resistance, such as TNF-α and resistin [8, 10, 13–16].
Since central obesity is characterized by an enhanced
cardiovascular risk, and it is known that dysfunctions of
platelets and vascular smooth muscle cells (VSMC) are
deeply involved in athero-thrombosis [19–22], the purpose
of this review is to identify the actions of adipokines and
adipocytokines on these cells, focusing in particular on the
role of inﬂammation.
2. Role of Platelets in Thrombosis and
Inﬂammation
Plateletsareanuclearcellfragmentsreleasedfrommegakary-
ocytes, hematopoietic cells that diﬀerentiate and undergo
endomitosis [23, 24]. Despite the lack of nucleus, they
contain mRNA and spliceosomal components for mRNA
processing, as well as the translational machinery for protein
synthesis [23, 25]: this justiﬁes de novo synthesis by platelets
of diﬀerent mediators involved in the regulation of inﬂam-
matory and coagulant pathways including IL-1β, PAI-1, and
TF [26, 27].
As evidenced in Figure 1, platelets play a pivotal role in
the response to vascular injury through adhesion to exposed
subendothelial layer triggered by diﬀerent collagen types
and adhesive proteins such as von Willebrand factor (vWF),
ﬁbronectin, laminin, ﬁbulin and thrombospondin [26–29].
Activation of platelets by components of the subendothelial
matrix is linked to exposure of membrane glycoprotein
receptorsincludingGPIb/V/IXcomplexwhichinteractswith
vWF, integrin α IIbβ3 (GPIIb/IIIa) able to bind Arg-Gly-Asp
[RDG] domain of vWF and ﬁbrinogen, and GPVI which
ensures a stable anchorage with subendothelial matrix by
direct interaction with collagen [26–30]. Platelet activation
and formation of aggregates are triggered also by thrombin
[31], endogenous mediators released from storage granules
and erythrocytes such as adenosine 5-diphosphate (ADP),
and de novo synthesis of platelet activating factor (PAF), and
thromboxane A2 (TXA2)[ 30, 32–34].
As shown in Figure 2, activated platelets also release
inﬂammatory mediators from granules, including platelet-
derived growth factor (PDGF) and platelet factor 4 (PF-4)
[35–37].
Beyond acute activation as a consequence of vascular
injury, circulating platelets are actively involved in all phases
of the atherogenetic process, from atherosclerotic plaque
formation to plaque inﬂammation and rupture [28, 37–39].
In these conditions, platelet reactivity is increased by reactive
oxygenspecies(ROS)producedasaconsequenceofoxidative
stress, by reduction of endothelial antithrombotic properties
and by the increased availability of proinﬂammatory media-
tors, such as cytokines and chemokines [40, 41].
Actually, platelets release several mediators linking
thrombosis and vascular inﬂammation such as the RANTES
(regulated on activation, normal T-cell expressed and
secreted) chemokine, PDGF, PF-4, Transforming growth
factor-β (TGF-β ),CD40ligand(CD40L,CD154),P-selectin,
and TXA2 [35–37, 41].
RANTES recruits monocytes and T cells; in conjunction
with P-selectin this chemokine can be immobilized on
inﬂammed endothelial cells, thus inducing monocyte arrest
and migration [41].
PDGF, the major growth factor contained in platelets
[36–38], stimulates both migration and proliferation of
VSMC by co-operation with serotonin, and TGF-β [36, 42,
43], and is chemotactic for monocytes [38, 43]; its eﬀects
on VSMC are critical for the development of atherosclerotic
process [27, 37, 38].
PF-4—a member of the C-X-C chemokine subfamily—
exerts chemotactic eﬀects on monocytes, promotes
monocyte-to-foam cell diﬀerentiation [27, 35, 36], enhances
the binding of oxidized low density lipoproteins (LDL) to
vascular wall, and inhibits LDL degradation through the
LDL receptors [35, 44].
CD40L is a trimeric protein structurally related to TNF-
α superfamily stored in the α -granules of resting platelets
[45–49]. After platelet activation, it is rapidly exposed on cell
surface and cleaved to release the soluble fragment (sCD40L)
able to increase the stability of new platelet aggregates [49],
andtoactivatevascularinﬂammatorymechanismsbyinduc-
ing production of ROS, enhancing expression of adhesion
molecules Vascular Cell Adhesion Molecule-1 (VCAM-1),
Intercellular Adhesion Molecule-1 (ICAM-1), and E-selectin
in endothelial cells and VSMC, and increasing secretion of
cytokines, chemokines, matrix metalloproteinases (MMPs),
and procoagulant factors [45–48].
Several cell types—including endothelial cells, VSMC,
monocytes, neutrophils, B cells and ﬁbroblasts—bind
CD40L through the speciﬁc receptor CD40 [45, 50]. ThisMediators of Inﬂammation 3
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Figure 1:Mechanismsinvolvedinplateletadhesiontosubendotheliallayerandactivation.ThediagramillustratestheroleofvonWillebrand
factor (vWF), collagen and other proteins in platelet adhesion by linking to exposure of membrane glycoprotein receptors including
GPIb//V/IX complex, GPIIb/IIIa, and GPVI which ensures a stable anchorage with subendothelial matrix by interaction with collagen.
Plateletactivationandaggregationaretriggeredbythrombin,endogenousmediatorsreleasedfromstoragegranules,andsynthesisofplatelet
activating factor (PAF), and thromboxane A2 (TXA2). P2Y1/12, purinergic P2Y receptors; TPα, thromboxane α receptor; 5HT-2A, serotonin
(5-hydroxytryptamine)-2A receptor; PAR-1, protease-activated receptor-1; PAR-4, protease-activated receptor-4; α2 AR, α2 adrenoreceptor.
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Figure 2: Platelet components involved in the coagulation cascade and the atherosclerotic process. PDGF, platelet-derived growth factor;
TGFβ, transforming growth factor β; EGF, endothelial growth factor; bFGF, ﬁbroblast growth factor; VEGF, vascular endothelial growth
factor; IGF, insulin-like growth factor; IL-1β, interleukin-1β; PAI-1, plasminogen activator inhibitor 1; vWF, von Willebrand factor; GP,
glycoproteins; PECAM, platelet and endothelial cell adhesion molecule; CD40L, CD40 ligand (CD154); RANTES, regulated on activation,
normal T-cell expressed and secreted; MIP-1α, macrophage inﬂammation protein 1α; IL-8, interleukin-8; PF4, platelet factor 4.
receptor has been recently identiﬁed also in adipocytes
where it plays a relevant role in the crosstalk with resident
lymphocytes [51]; furthermore, circulating sCD40L levels
have been found at abnormally high levels in patients with
obesity, type 2 diabetes mellitus and atherosclerotic vascular
diseases [52–55].
P-selectin is stored in platelet α -granules [36] and, after
activation, rapidly translocated upon cell surface becoming
accessible to circulation; this phenomenon strengthens ini-
tial rolling contact between platelets and vessel wall and
promotes RANTES deposition on endothelial cells, thus
increasing monocyte recruitment [27–29, 41, 47, 56].4 Mediators of Inﬂammation
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Figure3:Generalfeaturesofcirculatingplateletmicroparticles(PMPs).PMPsarephospholipidmicrovesiclesof0.1–1microninsize,sheded
from parental cell fragments after stimulation with physiological agonists such as thrombin or collagen or exposure to shear stress (i.e., in
severe stenosis). PMPs express functional adhesion receptors, including GPIIb/IIIa (CD41), P-selectin (CD62P), CXCR4, and PAR-1 and
contain diﬀerent proteins and coagulation factors, thus exerting a role in the hemostatic response and in the interplay between coagulation
and inﬂammation. PMPs also simulate cytokine release and adhesion molecule expression in endothelial cells and contraction of VSMC.
Elevated levels of circulating PMPs have been described in patients with arteriosclerosis, acute vascular syndromes, diabetes mellitus, as well
as central obesity. GPIIb/IIIa, glycoprotein IIb/IIIa; GP Ib, glycoprotein Ib; CXCR4, chemokine (C-X-C motif) receptor 4; PAR-1, protease-
activated receptor-1; RANTES, regulated on activation, normal T-cell expressed and secreted.
Platelet stimulation by agonists or exposure to high
shear stress leads to formation and release of platelet-derived
membrane-coated vesicles termed platelet microparticles
(PMPs) [57, 58], which inﬂuence the activities of other cell
types both regionally and systemically [58]. As evidenced in
Figure 3, PMPs are lipid-protein complexes with a diameter
< 1μ m, composed by vesicular fragments of the plasma
membrane and α -granules [59]: their protein content
plays a relevant role in both hemostasis and inﬂamma-
tion, by facilitating coagulation, promoting platelet and
leukocyte adhesion to the subendothelial matrix, supporting
angiogenesis and stimulating VSMC [58–60]. These eﬀects
may contribute to the chronic inﬂammatory state which
characterizes atherosclerosis [58]; in particular, a portion of
platelet-derived IL-1β associated with PMPs stimulates the
production of chemoattractant molecules and cytokines and
the expression of speciﬁc adhesion molecules in endothelial
cells,thusenhancingtheirinteractionwithcirculatingleuko-
cytes and, therefore, their ability to trigger inﬂammatory
responses [61, 62]. Also the chemokine RANTES is delivered
to sites of endothelial injury via PMPs to promote monocyte
recruitment [56, 63].
3.AlterationsofthePlateletFunctionin
Central Obesity
Platelet hyperactivity is deeply involved in the increased
atherothrombotic risk of patients aﬀected by central obesity
and type 2 diabetes mellitus [20, 21, 64].
A variety of defects of platelet function—mainly related
toincreasedadhesivenessandactivabilityinvivoandreduced
sensitivity to physiological antagonists—has been identiﬁed
in central obesity, as recently reviewed [20, 21].
Mean volume of circulating platelets—a parameter
directly related to in vivo platelet activation [65]r e l e v a n tt o
predict myocardial infarction occurrence and mortality and
restenosis following coronary angioplasty [66]—is increased
in obese patients, independently of the presence of other
cardiovascular risk factors [66, 67]; furthermore, a positive
correlation between body mass index (BMI) and mean
platelet volume (MPV) has been found in obese individuals
[66–69], whereas weight loss may lead to a decrease in
platelet size and reactivity [68].
Increasing evidences indicate that the size of circulating
platelets deeply inﬂuences their hemostatic potential being
the response of larger platelets to aggregating stimuli more
rapid and the amount of released mediators increased
[65, 70].
Platelet volume, as well as other platelet parameters, are
mainly determinated during megakaryocyte fragmentation
in bone marrow [71, 72]. Even though the mechanisms
inﬂuencing magakaryocytopoiesis are not completely under-
stood, an involvement of inﬂammatory cytokines (including
interleukins -1, -3, -6, -8, -11, and -18), and of nitric
oxide (NO) has been shown in some studies [73, 74];
this phenomenon allowed to hypothesize that the increased
productionandreleaseofproinﬂammatorycytokines,aswell
as endothelial dysfunction of central obesity, might inﬂuence
megakaryocytopoiesis and circulating platelet volume [75].
The increased in vivo activation of circulating platelets
is mirrored by the enhanced expression of activation-
dependent adhesion molecules, and by increased plasma
concentrationsofsP-selectin;anotherindexofinvivoplatelet
activation—that is, urinary excretion of 11-dehydro-TXB2,
the major enzymatic metabolite of TXA2—is increased in
women aﬀected by visceral obesity, compared to non-obese
women [76].Mediators of Inﬂammation 5
Relevant defects of platelet function in central obesity are
related also to a reduced sensitivity to mediators—such as
insulin,prostacyclin(PGI2),andNO—whichinleansubjects
reduce platelet sensitivity to proaggregating stimuli [21].
Insulin, which physiologically reduces platelet responses
to agonists both in vitro [77–79]a n din vivo [77, 80,
81], mainly through a NO-dependent mechanism mediated
by the increase of intraplatelet cyclic nucleotides 3 ,5   -
cyclic guanosine monophosphate (cGMP) and 3 ,5   -cyclic
adenosine monophosphate (cAMP) [78, 82], exhibits a
deeply impaired antiaggregating eﬀect in insulin resistant
states, such as central obesity, type 2 diabetes mellitus with
obesity and essential arterial hypertension [81, 83–85].
Furthermore, platelets from obese subjects or obese type
2 diabetic patients show defective responses to the NO/cyclic
nucleotide/protein kinase pathway including the ability of
NO and NO donors to increase cGMP, the ability of cGMP
to reduce platelet calcium and consequently aggregation
[86, 87]; similarly, also the ability of PGI2 to increase cAMP
and of cAMP to reduce platelet function are impaired in
these patients [87].
As previously mentioned, a relevant factor causing
plaletet dysfunction is the increased oxidative stress [40],
which is present in central obesity, as a consequence of
imbalance between ROS production and reduced levels of
substances able to protect from the damage of free radicals
and peroxides [88]. Several metabolic abnormalities of the
patients with visceral obesity—that is, excess of circulating
free fatty acids, of oxidized LDL, and of proinﬂammatory
adipokines and cytokines—contribute to ROS production
[88, 89].
Some adipokines and inﬂammatory cytokines such as
TNF-α and leptin are involved in enhanced oxidative stress
[88, 89]; furthermore, the increase in fat mass, as well as
the pathological secretion pattern of adipocytes decrease the
availabilityofantiinﬂammatoryproteinssuchasadiponectin
and ghrelin, which exert also protective eﬀects against
oxidative stress [15, 90, 91].
High concentrations of ROS inﬂuence platelet func-
tion by diﬀerent mechanisms, including decreased NO
bioavailability,calciummobilizationabnormalitiesandover-
expression of membrane glycoproteins [40, 92–94].
Isoprostanes are a family of prostaglandin-like metabo-
lites produced in vivo from esteriﬁed arachidonic acid
of cell membrane phospholipids or lipoproteins [95, 96]
through a ROS-dependent mechanism [96–99], completely
independent of cyclo-oxygenase-1 (COX-1) activity [95–97].
Once released, they circulate in plasma and are available for
receptorial interaction with platelets and cells of the vascular
wall; in particular, 8-iso-prostaglandin-F2α (8-iso-PGF2α ),
which is an abundant isoprostane compound formed in
vivo in humans, induces vasoconstriction and ampliﬁes the
adhesive reactions and the aggregating responses of human
platelets to agonists [100, 101].
Several studies showed a stimulatory interaction of iso-
prostaneswithTXA2 receptors[102,103],whichisprevented
by TXA2 receptor antagonism but not by COX-1 inhibition
[99]. Recently, a further isoprostane binding site, responsible
of cAMP reduction, has been recognized [103].
The increased levels of F2-isoprostanes observed in vis-
ceralobesity[104–107]canbeinvolvedbothinthepersistent
platelet activation in vivo [104], and in the resistance to
antiplatelet eﬀects of aspirin [21].
4. Alterationsof the Vascular Smooth Muscle
CellsinObesity
4.1. Role of Vascular Smooth Muscle Cells in Physiologi-
cal Conditions. In physiological conditions VSMC play an
essential role in providing structural integrity of the vessel
wall and in controlling vascular tone and blood pressure
[108, 109]; in particular, this cell type is the main target of
the eﬀects of endothelium-released NO, which stimulates the
synthesis of cGMP, thus preventing the calcium release from
intracellular stores [110, 111]. The inhibition of calcium-
dependent Rho/Rho kinase pathway is a relevant mechanism
involved in the modulation of VSMC relaxation induced by
the NO/cGMP/PKG pathway [112].
The surface complex system which regulates VSMC
responses and modulates the contractile process involves the
expression of receptors for catecholamines, acetylcholine,
serotonin, histamine, purinergic mediators, angiotensin II
(Ang II), bradykinin, neuropeptide Y, Vasoactive Intesti-
nal Polypeptide (VIP), vasopressin, oxytocin, prostanoids,
leukotrienes, and growth factors [PDGF, Epidermal Growth
Factor (EGF), TGF-β, Fibroblast Growth Factor (FGF),
insulin, and Insulin-like Growth Factor (IGF-1)] [113, 114].
The signal transduction system following membrane acti-
vation is played by guanine nucleotide regulatory proteins,
phosphoinositide metabolism, cyclic nucleotides (cAMP and
cGMP), and calcium [113, 114].
Diﬀerent agonists modulate VSMC responses by acti-
vating tyrosine kinases through receptor and nonreceptor
mechanisms. In particular, IGF-1 through its speciﬁc recep-
tor leads to direct activation of extracellular signal regulated
kinases (ERK 1/2), whereas Ang II and other mediators
activate tyrosine kinase pathway by indirect mechanisms
such as increased hydrogen peroxyde (H2O2)p r o d u c t i o n
mediated by NADPH oxidase [113, 114].
Furthermore, VSMC which exhibit functional insulin
receptors able to activate the classical signaling pathways—
that is, Insulin Receptor Substrates/phosphatidylinositol 3-
kinase (IRS/PI3-K) pathway and Mitogen-Activated Protein
Kinase (MAPK) pathway [115–118], are targets of insulin
action [115]. Through the PI3-K pathway, insulin stimulates
glucose transport, induces the well-diﬀerentiated contractile
state, antagonizes the eﬀects of PDGF and increases NO
production through NO synthase (NOS) activation [22, 78,
115, 116]; in the presence of PI3-K inhibitors, insulin, via the
MAPKpathway,inﬂuenceschemotaxis[117],DNAsynthesis
and proliferation [118–120].
In our previous studies in cultured human and rat arte-
rialVSMC,weobservedthatinsulin,throughNOSactivation
with PI3-K-dependent mechanism, elicits a concentration-
dependent increase of cGMP levels, increases cAMP content,
and enhances the eﬀects of the PGI2 analogue Iloprost, of
β -adrenoceptor agonists and of forskolin on cAMP levels6 Mediators of Inﬂammation
[22, 78, 84]. Insulin attenuates also the agonist-induced
increase of intracellular calcium by inhibiting the inositol-
triphosphate sensitive calcium release from intracellular
stores and by some other biochemical mechanisms mediated
by the PI3-K pathway [22, 78, 84, 115].
Furthermore, insulin can inﬂuence the hemodynamic
balance also through the synthesis and secretion of vasocon-
s t r i c t i v ea g e n t ss u c ha sE T - 1[ 22, 78, 84, 115].
Finally, via the cooperation of the two pathways, insulin
activates the Hypoxia Inducible Factor (HIF)/Vascular
Endothelial Growth Factor (VEGF) pathway [22, 78, 121,
122].HIF-1representsa“masterswitch”proteingeneratedin
response to hypoxia, able to inﬂuence erythropoiesis, vaso-
motion, glucose metabolism, cell proliferation and survival,
iron metabolism and angiogenesis; in normoxic conditions,
the HIF-1 system is also induced by cytokines and growth
factors [123, 124]. VEGF is a mitogen and a survival factor
forendothelialcells,abletoinducevascularpermeabilityand
to regulate physiological and pathological angiogenesis, with
a particular role in the postischemic revascularization [125].
4.2. Vascular Smooth Muscle Cells in the Pathogenesis of
Atherosclerosis. Following repeated or chronic arterial wall
injury, such as in arterial hypertension and exposure to other
cardiovascularrisk factors,VSMC respond by migration into
the intima, secretion, as well as by increased proliferation
[38, 126, 127].
VSMC migration to the intima from the media
depends on mechanisms regulated by soluble growth fac-
tors/chemoattractants, as well as by interactions with extra-
cellularmatrix [38,126,127]. The secretion process increases
extracellular matrix formation as well as the release of
proteins involved both in the digestion of major components
of the extracellular matrix, such as MMPs [128–130], and in
a n g i o g e n e s i s ,s u c ha sH I F - 1a n dV E G F[ 131–134].
A stimulating role on VSMC is exerted by cytokines
and growth factors, including IL-1β,I L - 6 ,T G F - β 1, TNF-α,
thrombin, bFGF, IGF-1, PDGF, urokinase plasminogen
activator (u-PA), Ang II, and VEGF [38, 126, 127, 133–137];
cytokine-dependent activation, in particular, increases the
synthesis of MMPs and their processing from inactive
zymogens to the active enzymes [128–130, 138–141]; the
same eﬀect has been recently described for C-reactive
protein (CRP) [140], and for sCD40L, which increases
VSMC proliferation and migration through the MMP-9
pathway [47, 142].
Enhanced proliferation of VSMC has been considered
for many years only a mechanism involved in atheroscle-
r o t i cp l a q u ef o r m a t i o n ;h o w e v e r ,s i n c ep l a q u e sp r o n et o
rupture (the so called “unstable” plaques) show a paucity
of VSMC compared with the “stable” ones [143], it has
been recently recognized a beneﬁcial role of VSMC also
in plaque stabilization and therefore in one of the main
mechanisms involved in the prevention of cardiovascular
events which are the consequence of plaque rupture and
superimposed thrombosis [144]. In recent years, the role
of VSMC apoptosis within the atherosclerotic plaques [145,
146], has been considered one of the major causes of plaque
rupture by thinning the ﬁbrous cap [147, 148]. Furthermore,
VSMC apoptosis has proinﬂammatory eﬀects and increases
macrophage inﬁltration through the release of IL-1α and the
up-regulation of MCP-1 and interleukin-8 (IL-8), responsi-
ble of macrophage inﬁltration in vivo [146, 148, 149]; in vitro
studies showed that VSMC apoptosis also promotes both
thrombin generation [150], and vascular calciﬁcation [151].
Finally, through the generation and release of
microparticles, apoptotic vascular cells are thrombogenic
locally, thus contributing to increase the thrombogenic
potential of the lipid core [152], and systemically [153];
evidences from in vitro studies support this eﬀects by
showing that microparticles containing TF are released by
cultured VSMC in response to stimuli mimicking minimal
apoptosis or ﬂow conditions [154].
Migration and proliferation of VSMC are also under
the inhibitory control of the nuclear receptors Peroxisome
Proliferator-activated Receptor (PPAR) alpha [155, 156]a n d
gamma [157].
4.3. Impairment of Vascular Smooth Muscle Cells in Insulin
Resistance States and Obesity. In obese subjects several
studies showed an impaired arterial vasodilation, mainly
involving cerebral, mesenteric, coronary, and skeletal muscle
districts [158, 159]; a pivotal role in this phenomenon is
played by endothelial dysfunction related to increased secre-
tionofproinﬂammatorycytokines,reducedcirculatinglevels
of adiponectin, and enhanced release of free fatty acids: all
these abnormalities alter gene expression and cell signaling
in vascular endothelium, cause vascular insulin resistance,
modify the release of endothelium-derived factors, and
increase vascular oxidative stress [158–163]. In particular,
the altered pattern of adipocytokine secretion characterizing
central obesity—that is, reduced adiponectin and elevated
levels of leptin, resistin, TNFα, and IL-6—increases the
production of superoxide anion (O2
− ), that interferes with
NO availability, thus reducing vasodilation [163, 164].
Furthermore, insulin resistance, which characterizes
human obesity and involves also the vascular eﬀects of
the hormone [115, 123, 165, 166], can determine per se
hemodynamic consequences by impairing the balance
between the vasodilating insulin actions exterted via the
NO/cGMP/PKG pathway and the vasoconstricting-ones
mainly exerted via ET-1 in favour of the last-ones, as
extensively reviewed [22, 78, 84, 115, 123, 167].
Since VSMC from animal models of insulin resistance
show alterations in mechanisms involved in vasodilation,
migration, and proliferation, a role of these vascular cells
in hemodynamic alterations of obesity cannot be ruled out
[22].
As previously mentioned NO/cGMP/PKG pathway plays
a key role in VSMC-dependent vascular responses in physi-
ological states [110, 111]: in particular, PKG initiates several
phosphorylation events leading to VSMC relaxation through
a reduction of free intracellular calcium levels, a decreased
sensitivity of the contractile apparatus to calcium, a rear-
rangement of cytoskeleton, a dephosphorylation of myosin
light chain, and a phosphorylation of two ﬁlament-actinMediators of Inﬂammation 7
binding proteins, Vasodilatory-Stimulated Phosphoprotein
(VASP) and the 20-kDa heat shock-related protein (HSP-
20) [111]. PKG is also involved in VSMC proliferation and
diﬀerentiationviaitsabilitytomodulategeneexpressionand
protein synthesis [111].
Studies from our laboratory showed that VSMC from
obese, insulin-resistant Zucker fa/fa rats—the classical ani-
mal model of insulin resistance due to defects in lep-
tin receptors—show a reduced insulin ability to increase
NO synthesis [121], and a reduced response to the
NO/cGMP/PKG pathway [168]. In particular, VSMC from
obese Zucker fa/fa rats shows: (i) baseline higher cGMP
concentrations due to a reduced catabolism by phosphodi-
esterases;(ii)impairmentoftheNOabilitytoincreasecGMP
by activating the soluble guanylate cyclase; (iii) reduction of
the NO and cGMP ability to activate PKG, as mirrored by
a reduced ability to phosphorylate VASP at serine 239 and
to activate phosphodiesterase 5 [168]. Interestingly, we also
observed that VSMC from obese insulin-resistant Zucker
fa/fa rats also show higher levels of O2
−, and that antiox-
idants prevent the multiple defects of the NO/cGMP/PKG
pathway, whereas H2O2 reproduces these defects in VSMC
from lean, insulin sensitive Zucker fa/+ rats [168]: these
data support the pivotal role of oxidative stress in the
reduced response to NO in this animal model of obesity and
insulin resistance, and can explain the reduced endothelium-
independent relaxation observed by some authors in these
animals in vivo [169].
Other investigations in animal models showed that
increased proliferation and migration of VSMC are a main
feature accounting for atherogenic arterial lesions in insulin
resistant states [170, 171]. In a rat model of obesity and type
2 diabetes mellitus, it has been described both a numerical
increase and functional abnormalities in intimal VSMC and
the occurrence of VSMC accumulation in atherosclerotic
lesions, with a direct correlation between VSMC prolif-
eration and insulin concentrations [170, 172, 173]; the
involvement of endogenous cytokines (especially TNF-α ),
a n dt h er e c e p t o r so fa d v a n c e dg l y c a t i o ne n dp r o d u c t s( A G E )
[RAGE] in neointimal formation in obese Zucker rats has
been recently recognized [174].
These observations are clinically relevant for the insulin
resistant patients who undergo revascularization procedures
incoronaryarteriesandinothervasculardistricts[175–177],
since VSMC migration and proliferation lead to excessive
neointima formation, which is the primary mechanism
responsible of restenosis [176]. It has also been observed
that in patients with type 2 diabetes the compensatory
hyperinsulinemia associated with insulin resistance strongly
predicts neointimal VSMC proliferation [178], and that
insulin resistance and endothelial dysfunction are indepen-
dent predictors of early restenosis after coronary stenting in
humans [179].
5. Inﬂuence of Adipocytokines on Platelets and
Vascular Smooth MuscleCellsinObesity
As previously mentioned, the altered pattern of adipocyte-
derived hormones and cytokines is deeply involved in the
chronic proinﬂammatory state characterizing patients with
central obesity and partially accounts for their increased
cardiovascular risk [5–7, 9–11, 15, 18].
Changes in adipocyte-derived factors enhance oxidative
stress by activating oxidases, interfere with NO availability
and inﬂuence cell proliferation and apoptosis [91, 171, 180,
181].
Several evidences indicated that adipokines and
cytokines inﬂuence platelet production and responses and
VSMC function. In this part of the paper we will focus on
the eﬀects of the diﬀerent adipocytokines on these cells
deeply involved in atherogenesis and atherothrombosis.
5.1. Interleukin-6 (IL-6). Interleukin-6 (IL-6) is a multifunc-
tional proinﬂammatory cytokine produced by diﬀerent cell
types, including those present in adipose tissue [174, 182]:
adipose tissue, in particular, contributes to up to 35% of
circulating IL-6 levels [174].
In healthy individuals IL-6 expression is due to a tight
regulation dependent on a complex hormonal network
related to glucocorticoid and catecholamine secretion [182,
183].
IncreasedIL-6expressionandcirculatinglevelshavebeen
associated with a variety of diseases, including metabolic
and vascular diseases, such as central obesity, the metabolic
syndrome, type 2 diabetes mellitus, atherosclerosis and, in
particular, atherosclerotic coronary artery disease [182, 183].
IL-6—together with other cytokines—is a key risk factor
for the development of atherothrombotic diseases due to
its eﬀect in plaque development and destabilization via
release of other proinﬂammatory cytokines, oxidation of
lipoproteins by phospholipases, stimulation of acute phase
protein secretion, release of prothrombotic mediators, and
activation of MMPs [183, 184]. Moreover, the increased ROS
formation by vascular enzyme systems under proinﬂamma-
tory conditions may play a critical role in the cross talk
between IL-6 and other vasoactive substances, such as Ang
II and catecholamines [185–187].
5.1.1. IL-6 and Platelets. As far as megakaryocytopoiesis
is concerned, IL-6 acts synergistically with thrombopoietin
(TPO), other interleukins, and growth factors in promoting
the maturation of megakaryocyte precursors [188–192];
actually, in vivo administration of IL-6 to humans increases
circulating platelet counts [190, 192]. This eﬀect may explain
the association between the increased markers of chronic
inﬂammation and the elevated platelet count in obese
women [193]: this phenomenon has been considered pro-
thrombotic, since higher platelet counts are associated with
adverse clinical outcomes in patients with acute coronary
events [194].
AssummarizedinFigure4,IL-6isresponsibleofanacute
prothrombotic state [184, 195] through mechanisms involv-
ing: (a) increased expression of TF, ﬁbrinogen, factor VIII
and vWF; (b) activation of endothelial cells; (c) reduced lev-
els of hemostasis inhibitors, such as antithrombin and pro-
tein S [195]. Furthermore, IL-6 inﬂuences platelet function8 Mediators of Inﬂammation
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Figure 4: Mechanisms involved in the alterations of the coagulative balance induced by interleukin-6 (IL-6). IL-1, interleukin-1; IL-4,
interleukin-4; TNF-α, tumor necrosis factor-α;I F N - γ, interferon-γ; f VIII, factor VIII, vWF, von Willebrand factor; AT III, antithrombin III.
by enhancing thrombin-induced activation [195], and mod-
ulatesplateletresponsesbyincreasingROSproduction[174].
5.1.2. IL-6 and VSMC. IL-6 inﬂuences both vessel wall
cells and their progenitors; beyond its eﬀects on resident
endothelial cells, IL-6 exerts pro-angiogenic actions by stim-
ulatingmigrationandproliferationofcirculatingendothelial
progenitors [196].
As far as VSMC are concerned, proinﬂammatory medi-
ators increase in these cells synthesis and release of IL-6
[197]. Additionally, IL-6 exerts speciﬁc eﬀects on VSMC:
in particular, it is involved in growth factor-dependent
VSMC migration, by interplaying with VEGF and TNF-α
[198–200], and stimulates VSMC proliferation with PDGF-
dependent and -independent mechanisms [201, 202].
These eﬀects explain the clinical observation that
increased IL-6 levels both in coronary and systemic cir-
culation are a risk factor for restenosis after angioplasty
[203, 204].
5.2. Tumor Necrosis Factor-α (TNF-α). TNF-α is a
pleiotropic, proinﬂammatory cytokine, produced as
17kDa protein and secreted as a 51kDa trimer by a variety
of cells including not only adipose tissue (see below) but also
macrophages, natural killer cells, T-cells, endothelial cells
and VSMC [205]; its presence has been also recognized in
human atheroma [206].
Adipose tissue has been identiﬁed as one of the main
sources of TNF-α: the majority of TNF-α produced in
adipose tissue is derived from inﬁltrating macrophages and
not from mature adipocytes [8, 13–15, 207].
Several studies evidenced an increased TNF-α circulating
level both in obese nondiabetic subjects and in type 2
diabetic patients [13, 207–209] and hypothesized its involve-
ment in the pathogenesis of obesity-linked insulin resistance
[209–212].
As far as the TNF-α eﬀects on vascular function are
concerned, it has been observed that acute administration
of TNF-α exerts per se a vasodilatory eﬀect, but impairs
endothelium-dependent vasodilation in response to insulin
and acetylcholine in healthy humans [212–214]; further-
more, it inhibits the vasodilating actions of insulin in vessels
ofratskeletalmuscle[213–215];theTNF-αinterferencewith
endothelial-mediated vasodilation is also due to shortening
the half-life of eNOS mRNA in endothelial cells [215, 216]
and to the increase of ET-1 synthesis and spillower [216].
TNF-α induces inﬂammatory changes in vessel wall by
activating the transcription factor Nuclear factor-κβ (NF-
κ B) [217], which increases the expression of ICAM-1 and
VCAM-1, and the production of MCP-1 and M-CSF from
endothelial cells and VSMC.
Plasma TNF-α concentrations predict vascular damage,
sincetheyareassociatedwithearlyatherosclerosisinmiddle-
agedhealthymen[218];furthermore,elevations ofTNF-α in
the stable phase after myocardial infarction were associated
with an increased risk of recurrent coronary events [219].
5.2.1.TNF-αandPlatelets. InvitrostudiesshowedthatTNF-
α promotes platelet aggregation [220] and ROS production
mainly through activation of the arachidonic acid pathway
[221, 222].
Other data indicate that TNF-α inﬂuences platelet func-
tion also by increasing the secretion of leptin, which acts as
proaggregating hormone.
At present, the results from in vivo studies are not
conclusive and there are not evidences to identify TNF-α as
a prothrombotic or antithrombotic factor in human patients
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5.2.2. TNF-α and VSMC. Human VSMC are both source
and target of TNF-α [205] which, together with interferon-γ
and IL-1, stimulates IL-6 production by this cell type [224].
Through NF-κ Bp a t h w a y ,T N F - α increases synthesis/release
of MMP from VSMC [217]. Thus, TNF-α is deeply involved
in plaque inﬂammation and instabilization also by the
mechanisms involving VSMC as described in the ﬁrst part
of this review.
5.3. Leptin. Leptin is a 167-amino acid adipokine, primarily
synthesized and released by mature adipocytes, although
expressed also in many other tissues including muscle,
placenta and gastric epithelium. Its circulating levels are
highly correlated with BMI [225].
Leptin receptors have been identiﬁed both in the
hypothalamus and in extrahypothalamic tissues and its main
roleistoinformthebrainregardingtheamountofstoredfat,
thusprimarilyregulatingfoodintakeandenergyexpenditure
[226]; however, in obese humans increased leptin levels are
unable to induce weight loss: this phenomenon is attributed
to a selective resistance to its metabolic actions [227].
Leptin, which has a structural and functional relation
to proinﬂammatory cytokines such as IL-6, also inﬂuences
angiogenesis, inﬂammation, arterial blood pressure and
secretion of other adipokines [10, 180, 181, 207].
In animal models, chronic hyperleptinemia is involved in
oxidativestressbydecreasingplasmalevelsoftheantioxidant
enzyme paraoxonase-1, an activity linked to circulating
lipoproteins [228]. This leptin eﬀect is followed by increased
plasma and urinary concentration of isoprostanes reﬂecting
an increased oxidative stress [228]. Evidences for an involve-
ment of leptin in atherosclerosis have been recently provided
by direct leptin administration in apolipoprotein deﬁcient
mice [229] and by the ﬁnding that ob/ob mice which
lacked functioning leptin gene are resistant to atherosclerosis
despite the presence of obesity and diabetes [230]. Also
in humans, the vascular actions of leptin are considered
proatherogenic and the increase of its circulating levels due
toadiposityhasbeeninvolvedinthepathogenesisofvascular
damage [231].
At present, clinical investigations considered leptin as
an independent risk factor for cardiovascular [232–234]
and cerebrovascular diseases [235, 236], evidencing that its
plasma concentrations are independently associated with
the intima-media thickness of the common carotid artery
[237], and with the degree of coronary artery calciﬁcation
in patients with type 2 diabetes mellitus, after controlling for
adiposity and CRP [238, 239]; furthermore, hyperleptinemia
could be involved in the increased risk of postangioplasty
restenosis [179, 240].
5.3.1. Leptin and Platelets. The pro-thrombotic actions of
leptin in vivo are related to an inﬂuence on platelet func-
tion, and on coagulation/ﬁbrinolysis balance, resulting in
enhancedagonist-inducedplateletaggregationandincreased
stability of arterial thrombi [241–243].
The long form of the leptin receptor (Ob-Rb) is present
in human platelets and can be related to platelet activation
by a speciﬁc pathway downstream of leptin-induced Janus
kinase 2 (JAK2) activation including PI3-K and phos-
pholipases Cγ2 and A2, which inﬂuence cAMP hydrolysis,
GPIIb/IIIa expression, and thromboxane synthesis [241]:
these ﬁndings induced to consider circulating plaletets as a
major target of leptin action, suggesting a possible direct link
between obesity and thrombotic complication [241, 242].
Studies in vitro showed that leptin synergizes with
subthreshold concentrations of agonists—such as ADP and
thrombin—to induce platelet aggregation [242–245], but is
unable to directly aggregate platelets. The involvement of
leptin in the increased platelet activation in human obesity
is not universally accepted, since recent studies provided
conﬂicting results about platelet responsiveness to leptin in
overweight and obesity [246, 247]; actually, in one study
the eﬀect of leptin on ADP-induced platelet aggregation
is attenuated in obese individuals due to the receptor
desensitization [245], whereas diﬀerent results have been
provided in another report [247].
Normal weight subjects undergoing complete caloric
deprivation have an increased sensitivity of hemostatic
responses to leptin [248]: this phenomenon indicates that
the sensitivity of leptin receptors on platelet membranes
is inﬂuenced by body composition [248]. In light of this,
the resistance to leptin in overweight or obese patients
could represent a protective mechanism against the excess
pro-thrombotic stimulation produced by obesity-related
hyperleptinemia [249].
However, other mechanisms by which leptin may con-
tribute to vasculardamage—suchas inﬂammation, oxidative
stress, endothelial dysfunction, as well as increased sym-
pathetic tone—are preserved in obese subjects [240, 250–
252] and can contribute to pro-thrombotic action of leptin
[240, 253].
5.3.2. Leptin and VSMC. Leptin exerts hemodynamic
actions, even though its eﬀects on the arterial wall have not
been fully elucidated at present. Evidences in animals and
humans showed that leptin administration induces acute
vasodilation in diﬀerent vascular districts, including human
coronary arteries [207, 254, 255].
The involvement of a receptor-mediated NO release
from endothelium has been shown in several, but not all,
experimental models of leptin-induced vasodilation [255,
256]; despite the increase of NO release, acute leptin
administration induced blood pressure reduction only in
sympathectomized animals, likely for a compensatory acti-
vation of the sympathetic nervous system [256, 257]. Insulin
interacts with leptin to modulate vascular responses, mainly
by enhancing NO production by endothelium [258].
Due to the presence of active receptors in VSMC [259],
leptin induces VSMC migration, proliferation, and expres-
sion of MMP-2, as shown in human aorta in vitro [260];
furthermore, in vitro studies showed that leptin stimulates
osteoblastic diﬀerentiation of VSMC and hydroxyapatite
production, thus explaining the relationships between cir-
culating levels of leptin and the degree of coronary artery
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Indirect mechanisms responsible of other leptin eﬀects
on VSMC are referred to oxidative stress which can cause
endothelial or VSMC damage and stimulation of low-grade
vascular inﬂammation [262].
5.4. Adiponectin. Adiponectin is a 30-kDa protein collagen-
likemoleculethatsharessubstantialhomologywithsubunits
of complement factor C1q [207, 263, 264]. It is expressed
almost exclusively in mature adipocytes where is the most
abundant adipokine synthesized and released locally and in
the blood stream. It accounts for 0.01% of the total plasma
proteins in form of trimer, hexamer and high molecular
weight12-to18-mer[207,263,264].Adiponectinsynthesisis
detectable also in human and murine cardiomyocytes [265].
As opposite to the other adipokines, circulating
adiponectin is negatively related to the increase of fat mass
likelyowingtotheabnormalhormonalmilieumainlycaused
by the inhibitory eﬀects exerted by the increased local TNF-α
levels, by the oxidative stress and by the proinﬂammatory
state which prevail in central obesity [207, 264, 266, 267]; its
secretion is restored as a consequence of weight loss [267].
Adiponectin exerts insulin-sensitizing eﬀects by increas-
ing glucose uptake, NO production, and free fatty acid
oxidation [268–270] and shows an antiinﬂammatory activity
mainly through a cAMP-mediated interference with NF-κ B
signaling [271].
In vascular wall, the antiinﬂammatory properties of
adiponectin—whichaccountforitsantiatherogeniceﬀects—
reduce cell expression of adhesion molecules and scavenger
receptors [272, 273]. This phenomenon is mediated by
the inhibition of the eﬀects of TNF-α and Ang II on
both endothelial cells (expression of adhesion molecules,
protection,increaseofpermeability, productionofROS)and
macrophages (decrease of cytokine production mediated by
NF-κ B signaling) [268, 271, 272].
The vasculo-protective eﬀects of adiponectin have been
recently conﬁrmed in clinical studies, by showing that its
decreased levels contribute to the metabolic and vascular
abnormalities in obese subjects [264, 268, 274].
5.4.1.AdiponectinandPlatelets. Inanimalsadiponectinplays
ar o l ea sa n t i t h r o m b o t i cf a c t o r[ 275]. Actually, there is
an accelerated thrombus formation after carotid arterial
injury in adiponectin knockout mice in comparison to wild-
type ones: the potential involvement of platelets in this
eﬀect is suggested by the presence of active adiponectin
receptors AdipoR1 and AdipoR2 in wild-type mice and by
the enhanced platelet response to ADP and collagen in
adiponectin knockout animals [275]. The same receptors
are present in isolated human platelets and in human
megakaryocytic cell lines; in humans, however, adiponectin
does not inﬂuence platelet activation by ADP and collagen
[276].
It has been hypothesized that adiponectin exerts indirect
anti-thrombotic eﬀects by decreasing the circulating concen-
trations of TNF-α and IL-6 and by interfering with their
pro-thrombotic activities, mainly dependent on increased
oxidative stress and decreased NO bioavailability [20, 277,
278].
5.4.2. Adiponectin and VSMC. Adiponectin suppresses pro-
liferation and migration of smooth muscle cells by directly
binding to several growth factors, particularly PDGF BB,
FGF, and heparin-binding epidermal growth factor-like
growth factor (HB-EGF) [279, 280].
Following experimental vascular injury, immunohisto-
chemical analysis shows the presence of adiponectin in the
walls of the catheter-injured vessels but not in intact vascular
walls [281]; thus, it can be hypothesized that adiponectin
secreted from adipose tissue reaches the injured arteries after
the lesion of the endothelial barrier and accumulates in
vascular walls, thus reducing the atherogenic process [281].
Finally, adiponectin may favor plaque stabilization
decreasingMMPactivitybymodulatingtheexpressionofthe
Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) through
increased IL-10 secretion [282].
5.5. Ghrelin. Ghrelin is a 28-amino acid peptide hormone,
predominantly producedbythestomach[283],whichactsas
a natural ligand of the Growth Hormone (GH) secretagogue
(GHS) receptor type 1a (GHS-R1a), and plays a role in
the central control of appetite together with leptin [284].
Circulating ghrelin levels are inversely related with degree of
obesity evaluated by BMI [285].
More recently, it has been demonstrated that ghrelin
also inﬂuences the cardiovascular system, by decreasing
sympathetic activity and producing vasodilation through an
endothelium-independent mechanism [286].
Furthermore, ghrelin exerts antiinﬂammatory eﬀects
in vessels, improves left ventricular function and shows
antiapoptotic actions on cardiomyocytes [286].
It has been suggested that the decrease of ghrelin in obese
patients is involved in their enhanced cardiovascular risk
and that ghrelin administration exerts protective eﬀects in
patients with obesity-related metabolic syndrome [287].
5.5.1. Ghrelin and Platelets. The protective cardiovascular
eﬀects of ghrelin likely do not involve platelets, since in vitro
thishormonedoesnotaﬀectplateletaggregationoradhesion
[276].
5.5.2. Ghrelin and VSMC. VSMC are targets of ghrelin,
which inhibits in vitro Ang II-induced proliferation and
contraction in a dose-response manner via the cAMP/PKA
pathway [288], and prevents vascular calciﬁcation in rats
[289].
5.6. Apelin. Apelin is an endogenous peptide ligand for
the orphan G-coupled APJ receptor, which exhibits close
homologywiththeangiotensin-like1receptor[290].Itexists
at least in three molecular forms, consisting of 13, 17, or
36 amino acids, all originating from a common 77-amino
acid precursor, and is present in several tissues, primarily
in the vascular endothelium [290]. Recently, apelin has been
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is increased by insulin, steroids and TNF-α [292, 293]. Its
synthesis and release are up-regulated in obesity, whereas
its expression in adipose tissue and its circulating levels are
reduced by weight loss [292].
Apelinismainlyconsideredavascularhormone:actually,
it induces an endothelium-dependent vasodilation [294,
295], exerts inotropic eﬀects [296], and plays a protective
role in the pathogenesis of heart failure by modulating the
harmful eﬀects of Ang II [294, 295].
Apelin is down-regulated in patients with heart failure
and up-regulated by a favourable left ventricular remodeling
[295].
The role of apelin-APJ system in atherogenesis is con-
troversial. Some apelin actions—including modulation of
endothelial oxidative stress and macrophage activation, NO-
dependent vasorelaxation and reduction of arterial blood
pressure [295, 297, 298]—are clearly protective, whereas
other eﬀects on arterial vessels might be detrimental by
favouring the atherogenic damage [299].
5.6.1. Apelin and VSMC. In the vascular system, the apelin-
APJ system is expressed in both endothelium—where it is
mitogenic [300] — a n di nV S M C[ 301]. Acute apelin admin-
istration in man causes NO-mediated arteriolar vasodilation
[294]. At present, data about the direct eﬀects of apelin on
VSMC are incomplete; it has been suggested an inﬂuence
on myosin light chain phosphorylation via APJ receptors,
responsible of vasoconstriction [302], and a proliferative
eﬀect on VSMC, induced by oxidative stress [299, 303].
5.7. Visfatin. Visfatin, previously recognized as a protein
involved in immune B-cell maturation [pre-B cell colony-
enhancing factor (PBEF)] [304], is abundantly expressed in
visceraladiposetissueandisup-regulatedinsome,butnotin
all, the animal models of obesity [305]. Preliminary studies
suggest that plasma visfatin concentrations are increased in
humans aﬀected by abdominal obesity and type 2 diabetes
mellitus [306, 307].
Although it is not a cytokine, visfatin expression
is up-regulated by cytokines: several studies showed its
involvement in metabolic and vascular homeostasis [308,
309]. Metabolic insulinomimetic eﬀects, characterized by
reduction of hepatic glucose production and stimulation
of peripheral glucose utilization, has been attributed to
binding to insulin receptor at a site diﬀerent from that
of insulin [308], even though recent results excluded
a visfatin-dependent direct activation of insulin signal-
ing pathway and attributed its action to nicotinamide
phosphoribosyltransferase activity (Nampt) [310]. Vascu-
lar eﬀects are both chronic and acute (see Figure 5):
chronic exposure to high visfatin concentrations—such
as in obesity and in type 2 diabetes mellitus—promotes
endothelial dysfunction, angiogenesis and atherosclerotic
plaque instabilization, whereas acute visfatin administration
stimulates eNOS expression and activity in endothelial
cells [309] and directly protects cardiomyocytes against
the detrimental eﬀects of acute ischemia-reperfusion injury
[311].
5.7.1. Visfatin and VSMC. Visfatin inﬂuences VSMC pheno-
typematurationfromaproliferativenoncontractiletoanon-
proliferative contractile one required for vasomotor function
[312], and promotes VSMC proliferation in perivascular
adipose tissue by a paracrine mechanism [313].
5.8. Resistin. Resistin has been originally identiﬁed as an
adipocyte-secreted peptide able to induce insulin resistance
in rodents; in humans it is represented by a 12.5kDa
cysteine-rich protein of 108 amino acids [314]. Also in
humans resistin is produced by adipose tissue and may act
both in paracrine and in endocrine fashion [314]: however,
in contrast to mice, only a low level of expression of resistin
has been found in mature adipocytes in humans [315, 316].
Furthermore, resistin expression has been demonstrated
in bone marrow, trophoblastic cells of placenta, pancreas,
synovial tissue, and circulating blood cells [317].
Resistinisanimportantregulatorofglucosehomeostasis,
adipogenesis,and,potentially,inﬂammation[317];inpartic-
ular, it can induce insulin resistance by regulating adipose
tissue deposition through a negative feedback mechanism
[317], and exerts proinﬂammatory eﬀects through activation
of the transcription factor NF-κ B[ 318].
The interplay between resistin and vascular wall cells can
potentially contribute to the development of atherosclerotic
lesions (Figure 6): in particular, it favors angiogenesis by
inducing endothelial cell growth activation and migration,
mainly by increasing ET-1 release [319, 320], and potentiat-
ing the eﬀect of CD40L [321]; furthermore, it is involved in
lipid storage in macrophages [317, 322].
5.8.1. Resistin and VSMC. Resistin induces proliferation of
culturedhumanaorticVSMCthroughbothERK1/2andAkt
signaling pathways [323]. Furthermore, hypoxia increases
resistin expression in cultured rat VSMC [323].
5.9. Endothelin. Increased circulating levels of ET-1 have
been observed in patients aﬀected by central obesity and
metabolic syndrome [324]. ET-1 elevation is proportional
to hyperinsulinemia [324, 325], and weight loss by diet
intervention reduces both serum insulin and ET-1 [326].
The increase of ET-1 accounts for a prevailing vaso-
constrictive eﬀect of insulin in insulin resistant states,
in which the insulin-induced, PI3-K-mediated increase of
NO is impaired [325]; furthermore, ET-1 contributes per
se to vasoconstriction by inﬂuencing calcium ﬂuxes, by
activating the renin-angiotensin system, and by inducing
VSMC hypertrophy [327].
5.9.1. ET-1 and Platelets. Platelets are a potential target of
circulating ET-1. However, as recently reviewed, ET-1 eﬀects
on platelets are still conﬂicting [328]: some studies showed
that in vitro exposure to ET-1 induces platelet activation
or increases platelet responses to aggregating agonists [327–
329], other studies, however, failed to detect any direct eﬀect
[329] or even showed a decrease in platelet responses [328].
These conﬂicting results may be due to complex interac-
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Figure 5: Acute and chronic cardiovascular eﬀects of visfatin. VEGF, vascular endothelial growth factor; MMP-2, matrix metalloproteinase-
2; MMP-9, matrix metalloproteinase-9; PBEF, pre-B cell colony-enhancing factor I-R, ischemia-reperfusion.
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Figure 6: Potential vascular eﬀects of resistin. IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-α; ET-1, endothelin-1;
MCP-1, monocyte chemoattractant protein-1; VCAM-1, Vascular Cell Adhesion Molecule-1; ICAM-1, Intercellular Adhesion Molecule-1;
MMPs, matrix metalloproteinases.
5.9.2. ET-1 and VSMC. VSMC are both a source and a
target of ET-1 [330–333]. As recently reviewed [333], ET-1
stimulates VSMC proliferation [334], migration [335], con-
traction[336],extracellularmatrixsynthesis andremodeling
[337, 338], and expression of other proatherogenic growth
f a c t o r ss u c ha sP D G Fa n dT G F - β [339].
6. Conclusions
Themajoradverseconsequencesofcentralobesityarerelated
to the development of type 2 diabetes mellitus and of athero-
thrombotic vascular diseases, which account for a high
disease-related mortality [1, 5–7]. As extensively conﬁrmed,
the main alterations of central obesity involved in vascular
damage are recognized in the impaired systemic metabolic
homeostasis as well as in the presence of an active low-grade
chronic inﬂammatory process in tissues that are relevant for
metabolism, such as adipose tissue, liver, muscle and arterial
wall [6, 11, 13, 15, 19, 340].
In particular, the activation of an inﬂammatory process
by adipose tissue is related to impairment of the secretion
pattern of adipocytokines, including increased local avail-
ability of major cytokines [6, 7, 13, 14, 18, 340, 341], as
well as enhanced synthesis and secretion of proinﬂammatory
adipokines [13–15] and reduced availability of protective,
insulin sensitizing peptides, including adiponectin and ghre-
lin [2, 15, 340–343].Mediators of Inﬂammation 13
On the basis of the large number of reviewed studies,
a relevant role can be recognized to impairment of platelet
and VSMC functions in the pro-thrombotic tendency,
proinﬂammatory state and accelerated atherogenesis of the
patients with central obesity [20–22].
Impaired synthesis and/or secretion of single adipocy-
tokines which can interplay with platelets and VSMC are
deeply involved in these phenomena.
Asextensivelyreviewed,alargebodyofevidencesshowed
detrimental actions of the increased synthesis and secretion
of several mediators which act through pro-thrombotic and
proliferative actions and oxidative stress, including TNF-α,
interleukins and likely leptin [342]. However, also the lack of
the protective eﬀects of adipokines such as adiponectin and
ghrelin has to be considered another relevant feature of the
proatherogenic milieu characterizing the altered endocrine
pattern of the patients with central obesity. In particular,
adiponectin is a relevant anti-thrombotic adipokine, as
widely reviewed [266, 268, 343] and emerging evidences
underline ghrelin protective eﬀects on insulin resistance, car-
diovascular system, oxidative stress, and, likely, hemostatic
balance [20, 104, 105, 343]: therefore, the reduced levels of
this peptide in central obesity may be another deterimental
feature increasing cardiovascular risk in obese subjects.
In summary, available evidences allow to hypothesize
the presence of a complex scenario related to increased
atherogenic and atherothrombotic risk in central obesity: in
this context an impaired pattern of adipocytokine synthesis
and secretion, rather than alteration of single mediators, has
to be considered a major mechanistic link.
ReviewStrategyandSelectionCriteria
Searchesfororiginalarticlesandreviewsfrom1985toFebru-
ary 2010 focusing on obesity, hemostasis, vascular function
and adipokines were performed in MEDLINE and PubMed
electronic databases. The search terms were: “adipocy-
tokines”, “adipokines”, “adiponectin”, “apelin”, “cytokines”,
“central obesity”, “endothelin-1”, “ghrelin”, “insulin resis-
tance”, “interleukin-6”, “leptin”, “metabolic syndrome”,
“obesity”, “overweight”, “platelets”, “platelet dysfunction”,
“resistin”,“thrombosis”,“Tumornecrosisfactor-α”,“vascular
smooth muscle cells”, and “visfatin”. All papers identiﬁed
were English-language, full-text papers and were selected on
the basis of relevance and novelty; a priority was given to
those published in peer-reviewed journals.
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